Schechter Investment Advisors LLC Trims Position in ICON Public Limited (NASDAQ:ICLR)

Schechter Investment Advisors LLC lessened its stake in shares of ICON Public Limited (NASDAQ:ICLR) by 9.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 4,048 shares of the medical research company’s stock after selling 440 shares during the quarter. Schechter Investment Advisors LLC’s holdings in ICON Public were worth $1,146,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Laurel Wealth Advisors Inc. grew its holdings in shares of ICON Public by 2.0% during the first quarter. Laurel Wealth Advisors Inc. now owns 2,708 shares of the medical research company’s stock worth $658,000 after purchasing an additional 54 shares in the last quarter. KB Financial Partners LLC grew its holdings in shares of ICON Public by 23.4% during the first quarter. KB Financial Partners LLC now owns 1,742 shares of the medical research company’s stock worth $424,000 after purchasing an additional 330 shares in the last quarter. Captrust Financial Advisors lifted its position in ICON Public by 4.8% in the 2nd quarter. Captrust Financial Advisors now owns 28,338 shares of the medical research company’s stock worth $6,141,000 after buying an additional 1,296 shares during the last quarter. Alpha Paradigm Partners LLC bought a new stake in ICON Public in the 3rd quarter worth approximately $123,000. Finally, Chartwell Investment Partners LLC bought a new stake in ICON Public in the 4th quarter worth approximately $794,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

ICLR has been the subject of a number of recent research reports. Evercore ISI boosted their target price on ICON Public from $325.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, February 23rd. Truist Financial boosted their target price on ICON Public from $357.00 to $367.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Barclays boosted their target price on ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Mizuho boosted their price objective on ICON Public from $315.00 to $346.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Finally, Citigroup boosted their price objective on ICON Public from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Monday, December 11th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, ICON Public has an average rating of “Moderate Buy” and an average target price of $312.64.

ICON Public Trading Down 0.1 %

NASDAQ ICLR opened at $329.50 on Thursday. ICON Public Limited has a 12 month low of $181.92 and a 12 month high of $344.77. The stock has a market cap of $27.18 billion, a P/E ratio of 44.65, a P/E/G ratio of 1.54 and a beta of 1.15. The stock’s fifty day moving average price is $300.71 and its 200-day moving average price is $273.83. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.40.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, February 21st. The medical research company reported $3.40 EPS for the quarter, topping analysts’ consensus estimates of $3.27 by $0.13. ICON Public had a return on equity of 11.42% and a net margin of 7.54%. The firm had revenue of $2.07 billion for the quarter, compared to analysts’ expectations of $2.08 billion. As a group, equities analysts forecast that ICON Public Limited will post 14.4 EPS for the current fiscal year.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.